|1.||Shioda, Seiji: 6 articles (11/2014 - 04/2004)|
|2.||Nakamachi, Tomoya: 6 articles (11/2014 - 04/2004)|
|3.||Hori, Motohide: 4 articles (11/2014 - 01/2011)|
|4.||Kagami, Nobuyuki: 4 articles (11/2014 - 01/2011)|
|5.||Arata, Satoru: 4 articles (11/2014 - 07/2006)|
|6.||Imai, Nori: 3 articles (11/2014 - 11/2012)|
|7.||Watanabe, Jun: 3 articles (11/2014 - 07/2006)|
|8.||Tsuchikawa, Daisuke: 3 articles (01/2013 - 01/2011)|
|9.||Wada, Yoshihiro: 3 articles (01/2013 - 01/2011)|
|10.||May, Victor: 2 articles (06/2014 - 11/2008)|
04/01/2012 - "The present study reveals a previously uncharacterized role of PACAP to protect NSC from lipotoxicity and suggests a potential therapeutic role for PACAP receptor agonists in the treatment of neurological complications in obesity and diabetes."
09/01/2006 - "This study employed the PACAP receptor antagonist, PACAP(6-27) to evaluate the role of endogenous PACAP in genetic obesity-related diabetes and related metabolic abnormalities using ob/ob mice. "
12/15/2004 - "VIP/PACAP receptor visualization with this simple and rapid immunohistochemical method will facilitate identification of tumors with a sufficient receptor overexpression for diagnostic or therapeutic intervention."
12/15/2004 - "The distribution of VIP/PACAP receptors was investigated in 98 human tumors and their tissues of origin. "
04/01/1996 - "The expression of the PACAP receptor was demonstrated by direct binding studies and/or by the relative potency of PACAPs and VIP to stimulate adenylate cyclase activity in 16 of the 22 tumors and in all the cell lines. "
01/01/2008 - "Tumors from PACAP/ptc1 mutant mice retained PACAP receptor gene expression, and exhibited superinduction of Hh target genes compared to those from ptc1+/- mice. "
12/15/2004 - "However, none of the VIP/PACAP receptor proteins has been visualized individually in human tumors. "
|3.||Lung Neoplasms (Lung Cancer)
03/01/2003 - "VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: a study in biopsy specimens."
11/01/2012 - "PYK-2 is tyrosine phosphorylated after activation of pituitary adenylate cyclase activating polypeptide receptors in lung cancer cells."
06/01/2012 - "The activated PACAP receptor (PAC1) causes phosphatidylinositol turnover, elevates cAMP, and increases the proliferation of lung cancer cells. "
03/01/2003 - "This study examined the presence of VIP and PACAP receptors in human lung cancer samples, as well as the functionality of adenylyl cyclase (AC) stimulated by both peptides. "
|4.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/01/1994 - "Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23."
10/01/1994 - "The expression of the messenger RNAs coding for glucagon-like peptide-I (GLP-I) receptor, VIP receptor, and pituitary adenylate cyclase-activating polypeptide (PACAP) receptor as well as the expression of the receptor proteins were demonstrated in the rat medullary carcinoma of thyroid cell line 6/23 by the following experiments: 1) RNA extraction, reverse transcriptase, and polymerase chain reaction with specific primers; 2) binding of the radiolabeled ligands [125I]GLP-I-(7-36)-NH2, [125I]PACAP-(1-27), and [125I]VIP and inhibition by, respectively, unlabeled GLP-I-(7-36)-NH2, PACAP-(1-27), and VIP; and 3) study of adenylate cyclase activation by the peptides and selective inhibition of the VIP/PACAP response by the antagonist [D-Phe2]VIP. "
|1.||Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)
|2.||Adenylate Cyclase (Adenylyl Cyclase)
|4.||Vasoactive Intestinal Peptide Receptors (Vasoactive Intestinal Peptide Receptor)
|5.||Proteins (Proteins, Gene)
|6.||Type I Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
|7.||RNA (Ribonucleic Acid)
|8.||RNA-Directed DNA Polymerase (Reverse Transcriptase)